1. Home
  2. DVAX vs THRM Comparison

DVAX vs THRM Comparison

Compare DVAX & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • THRM
  • Stock Information
  • Founded
  • DVAX 1996
  • THRM 1991
  • Country
  • DVAX United States
  • THRM United States
  • Employees
  • DVAX N/A
  • THRM N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • THRM Auto Parts:O.E.M.
  • Sector
  • DVAX Health Care
  • THRM Consumer Discretionary
  • Exchange
  • DVAX Nasdaq
  • THRM Nasdaq
  • Market Cap
  • DVAX 1.3B
  • THRM 1.0B
  • IPO Year
  • DVAX 2004
  • THRM 1993
  • Fundamental
  • Price
  • DVAX $11.36
  • THRM $34.40
  • Analyst Decision
  • DVAX Buy
  • THRM Buy
  • Analyst Count
  • DVAX 4
  • THRM 3
  • Target Price
  • DVAX $26.25
  • THRM $50.33
  • AVG Volume (30 Days)
  • DVAX 1.6M
  • THRM 325.9K
  • Earning Date
  • DVAX 08-05-2025
  • THRM 07-24-2025
  • Dividend Yield
  • DVAX N/A
  • THRM N/A
  • EPS Growth
  • DVAX N/A
  • THRM N/A
  • EPS
  • DVAX N/A
  • THRM 1.02
  • Revenue
  • DVAX $294,620,000.00
  • THRM $1,453,370,000.00
  • Revenue This Year
  • DVAX $21.18
  • THRM N/A
  • Revenue Next Year
  • DVAX $16.83
  • THRM $4.04
  • P/E Ratio
  • DVAX N/A
  • THRM $33.46
  • Revenue Growth
  • DVAX 24.76
  • THRM N/A
  • 52 Week Low
  • DVAX $9.22
  • THRM $22.75
  • 52 Week High
  • DVAX $14.63
  • THRM $56.68
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 66.09
  • THRM 76.37
  • Support Level
  • DVAX $10.38
  • THRM $31.00
  • Resistance Level
  • DVAX $11.48
  • THRM $31.62
  • Average True Range (ATR)
  • DVAX 0.30
  • THRM 1.17
  • MACD
  • DVAX 0.08
  • THRM 0.27
  • Stochastic Oscillator
  • DVAX 90.40
  • THRM 99.00

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About THRM Gentherm Inc

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

Share on Social Networks: